OTC Markets Group (OTCM) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/08/25
OTC Markets Group Launches OTCID™ Basic Market, In Major Structural Upgrade to U.S. OTC Equities MarketsGlobeNewsWire • 07/01/25
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EUNewsfile Corp • 06/25/25
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 ConferenceNewsfile Corp • 06/20/25
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides UpdateNewsfile Corp • 06/17/25
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome SpectrumNewsfile Corp • 06/11/25
OTC Markets Group Welcomes Exail Technologies, a European defense company, to OTCQXGlobeNewsWire • 05/27/25